Information Provided By: 
Fly News Breaks for January 17, 2019
MD
Jan 17, 2019 | 08:48 EDT
Jefferies analyst Jason Plagman assumed coverage of Mednax with a Hold rating and lowered his price target for the shares to $39 from $44. While the analyst expects stable to slightly improving organic growth and margin trends in 2019, he believes slow birth trends and payor mix shifts are likely to continue to pressure MD's business model until physician comp is restructured. The valuation is "depressed" but the stock lacks near-term catalysts, Plagman tells investors in a research note.
News For MD From the Last 2 Days
There are no results for your query MD
